Early Pharmacodynamic Assessment Using ¹⁸F-Fluorodeoxyglucose Positron-Emission Tomography on Molecular Targeted Therapy and Cytotoxic Chemotherapy for Clinical Outcome Prediction

详细信息    查看全文

• 作者：Masaki Kanazu¹ ; Kaoru Maruyama² ; Masahiko Ando³ ; Kazuhiro Asami¹ ; Mari Ishii⁴ ; Kazutaka Uehira¹ ; Shojiro Minomo¹ ; Yoshinobu Matsuda¹ ; Tomoya Kawaguchi¹ ; Shinji Atagi¹ ; Yoji Ogawa⁵ ; Yoko Kusunoki⁶ ; Minoru Takada⁷ ; Akihito Kubo⁸ ; ^{kuboa@aichi-med-u.ac.jp" class="auth_mail}
• 关键词：Cytotoxic chemotherapy ; Epidermal growth factor receptor tyrosine kinase inhibitor ; Gefitinib ; Molecular targeted therapy ; Non&ndash ; small-cell lung cancer
• 刊名：Clinical Lung Cancer
• 出版年：May, 2014
• 年：2014
• 卷：15
• 期：3
• 页码：182-187
• 全文大小：440 K

文摘

Early prediction of therapeutic outcome is important in determining whether the ongoing therapy is beneficial. In addition to anatomical response determined using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, recent studies have indicated that change in tumor glucose use on or after treatment correlates with histopathologic tumor regression and patient outcomes. This Perspective discusses the use of ¹⁸F-fluorodeoxyglucose-positron emission tomography (FDG-PET) for pharmacodynamic evaluation in a very early phase of treatment to predict clinical outcomes in patients with advanced non-small-cell lung cancer. We conducted a study to assess whether early metabolic response determined using FDG-PET correlated with clinical outcomes in patients treated with gefitinib or those treated with carboplatin plus paclitaxel (CP). Early metabolic response to gefitinib, but not CP, correlated with the聽late metabolic response, anatomical response, progression-free survival, and even overall survival. A rapid effect of molecular targeted agents might not be aptly evaluated using the conventional criteria, eg, RECIST, in a very early phase of treatment before volumetric shrinkage of the tumor. Based on the findings of several studies, and on the聽findings from our study, use of FDG-PET might enable prediction of clinical outcomes at a very early stage of treatment, especially in patients treated with molecular targeted agents with rapid clinical efficacy.